DUXAP8 and hepatocellular carcinoma: The results indicated that increased DUXAP8 expression predicted poor OS in patients with low Mutation burden (Figure 2B), high Mutation burden (Figure 2C), Grade I (Figure 2D), Grade II (Figure 2E), Grade III (Figure 2F), Stage I (Figure 2G), Stage II (Figure 2H), and Stage III (Figure 2I) HCC.